Ask

Find medical evidence faster. With the sources it is based on.

Try AVOR for free Get in Touch

Free for medical professionals. Directly in the browser.

Developed by experts in hematology, oncology and data science. Our team →
avor.med
New research
What does the evidence say about treating AML with FLT3-ITD in patients under 60 with no further mutations?
Structured answer
Evidence overview: AML with FLT3-ITD, patients under 60
Includes guideline recommendations, EMA approval information and study data on induction and post-remission therapy in FLT3-ITD-positive AML without further mutations.
Guideline recommendations
Approval status (EMA)
Study data
Sources used
Guideline1
Open original source →
EMA2
Open original source →
Publication3
Open original source →
What would you like to research? Ask question

Illustrative product presentation with example research queries. Presentation and functionality may differ from the current version.

Evangelisches Klinikum Bethel (EvKB)
Göttingen Campus Institute for Dynamics of Biological Networks
Krankenhaus Mara
University Hospital OWL
GoeFuture

One question. Relevant information. Traceable sources.

AVOR brings together content from medical sources, structures it into an answer and keeps every statement linked to its original source. For medical professionals, with a focus on oncology and hematology.
Guidelines Approvals (EMA) Regulatory information (EMA) Studies Original publications
AVOR
brings together, structures and links every statement to its source
Structured evidence Traceable sources Faster access to clinical information

Where AVOR can help

Research guidelines

Find relevant recommendations for a medical question faster.

Research treatment options

Compile information on described treatment options in a structured way.

Find approval information

Search regulatory information from the European Medicines Agency (EMA) in a targeted way.

Compare evidence

Set statements from different medical sources side by side.

Prepare tumor boards

Compile relevant guidelines and regulatory information for professional preparation.

Put new developments in context

Grasp current medical information and its underlying sources faster.

Four steps

How AVOR works

01

Ask question

Phrase your question the way you would ask a colleague.

02

Find information

AVOR searches for information relevant to your question.

03

Read the answer

Results are presented in a structured, clear way.

04

Check sources

The sources used are shown for relevant statements, so you can trace and assess the information yourself.

avor.med
New research
What does the evidence say about treating AML with FLT3-ITD in patients under 60 with no further mutations? Ask question
AVOR is searching relevant sources.
Guidelines Regulatory information (EMA) Publications
Structured answer
Evidence overview: AML with FLT3-ITD, patients under 60
Includes guideline recommendations, EMA approval information and study data on induction and post-remission therapy in FLT3-ITD-positive AML without further mutations.
Guideline recommendations
Approval status (EMA)
Study data
Sources used
GuidelineSource 1
Open original source →
EMASource 2
Open original source →

Example of a research session with AVOR. Content and user interface are for illustration only.

What research with AVOR can look like.

avor.med
New research
What does the evidence say about first-line treatment of metastatic non-squamous NSCLC with PD-L1 TPS ≥ 50 % and no targetable driver alteration, and what data exist on liver and brain metastases?
Structured answer
Evidence overview: metastatic non-squamous NSCLC, PD-L1 TPS ≥ 50 %

For PD-L1 TPS ≥ 50 % and no targetable driver alteration, guidelines name PD-1/PD-L1 monotherapy or chemo-immunotherapy as first-line treatment. For high tumor burden and visceral metastases, they list the combination as an option.

Guideline recommendations
Pembrolizumab, atezolizumab or cemiplimab monotherapy are first-line options for PD-L1 TPS ≥ 50 %.[1]
As chemo-immunotherapy, guidelines name pembrolizumab plus pemetrexed and platinum-based chemotherapy, including for high tumor burden.[1]
According to the guideline, small asymptomatic brain metastases can initially be treated systemically with close MRI monitoring; local radiotherapy is decided in an interdisciplinary setting.[1]
Approval status (EMA)
Pembrolizumab is approved in the EU in combination with pemetrexed and platinum for metastatic non-squamous NSCLC without EGFR or ALK alterations.[2]
Study data
KEYNOTE-189: pembrolizumab plus chemotherapy improved overall and progression-free survival; patients with stable brain metastases were also included.[3]
IMpower150: data on atezolizumab, bevacizumab and chemotherapy in patients with liver metastases.[3]
Please note: the sequence of systemic and local therapy should be assessed individually and in an interdisciplinary setting, taking into account symptoms, steroid requirements and the size of brain metastases, among other factors.
What would you like to research? Ask question
Sources used
GuidelineSource 1
View sourceOpen original source →
EMASource 2
View sourceOpen original source →
PublicationSource 3
View sourceOpen original source →

Illustrative product presentation with example research queries. Presentation and functionality may differ from the current version.

Try AVOR for free

Experience evidence-based medical research with traceable sources.

AVOR is currently not a medical device. The application is intended for the structured research and preparation of medical information for healthcare professionals and is not intended for patient-specific diagnostic or treatment decisions.

Sources & evidence

Not just an answer. The source as well.

For medical questions in particular, a well-phrased answer is not enough. What matters is where the information comes from.

That is why AVOR shows the underlying sources and makes it possible to verify relevant information yourself.

Source
Which medical or regulatory source underlies the statement?
Currency
When was the information published or last updated?
Context
Which disease, treatment situation or patient group does the information apply to?
Traceability
How can the statement be verified in the original source?
1Source 1
2Source 1
GuidelineSource 1
Relevant passage
Open original source View source
Source types Medical guidelinesRegulatory information from the European Medicines Agency (EMA)Scientific literature
Our team

The team behind AVOR

Founding team and extended team combine clinical experience, science and technology.

Founding team

Medicine, technology and business development.

Prof. Dr. med. Florian Weißinger
Medical strategy & oncology
Prof. Dr. med. Florian Weißinger
Chief Executive Officer
Chief physician for hematology and oncology and head of the Oncology Center at Evangelisches Klinikum Bethel.

Many years of experience in oncology, stem cell transplantation and clinical strategy. Former board member of the DGHO. Responsible at AVOR for overall medical strategy and clinical direction.

DGHOOncologyStem cell transplantation
Friedrich Schwarz
Technology & medical AI
Friedrich Schwarz
Chief Technology Officer
Physician and data scientist at the Göttingen Campus Institute for Dynamics of Biological Networks.

His work combines medicine, data science, machine learning and computational neuroscience. First author of a paper published in npj Digital Medicine in 2026. Responsible at AVOR for technology, data and evaluation.

Medical AIData Sciencenpj Digital Medicine
Max Schüler
Operations & business development
Max Schüler
Chief Operating Officer
Dentist, founder and researcher in digital medicine at the Medical School OWL.

International clinical and research experience at Harvard, the University of Pennsylvania and Massachusetts General Hospital. Responsible at AVOR for operations, product delivery, financing and business development.

Digital MedicineOperationsEntrepreneurship
Dr. med. Enver Aydilek
Clinical medicine & validation
Dr. med. Enver Aydilek
Chief Medical Officer
Senior consultant for hematology and oncology at Evangelisches Klinikum Bethel.

Clinical and research experience in hematology, oncology, stem cell transplantation and real-world evidence. Responsible at AVOR for clinical application, medical validation and physician workflows.

HematologyReal-World EvidenceClinical Validation

The extended AVOR team

Interdisciplinary contributions beyond the founding team.

Competencies that come together

AVOR is created through the collaboration of people with different professional perspectives. Beyond our founding team, further contributors bring their expertise to the development and continuous improvement of the platform.

Competencies from medicine and science come together with technology, software development, artificial intelligence, product development and other fields. Together we work to make complex medical knowledge more accessible and to develop AVOR consistently along the needs of clinical practice.

Medicine & science
Technology & AI
Clinical Knowledge
Research & Evidence
Product development
UX & Product Design
Regulatory & Quality
Data & Knowledge Systems
Advisory Board

Scientific and clinical guidance

For its further professional development, AVOR is building an advisory board of renowned experts from various medical and scientific disciplines. These include experienced clinicians, professors and experts with experience in developing medical guidelines.

This way, clinical practice, scientific evidence and different professional perspectives continuously inform the further development of AVOR.

Clinical practice

Experience from day-to-day patient care.

Science

Perspectives from research and teaching across disciplines.

Guideline development

Experience in developing medical guidelines.

Our Vision

More evidence. More complexity. Limited time for research.

More and more people are being treated for or after cancer. At the same time, the evidence that decisions are based on is growing faster than the time available to review it.

517,800
New cancer cases in Germany in 2023
276,400 diagnoses in men, 241,400 in women.
Source: RKI/ZfKD, Epidemiologisches Bulletin 5/2026
49 % / 43 %
Lifetime risk of cancer, men and women
Almost every second man and more than two in five women develop cancer during their lifetime.
Source: RKI/ZfKD, cancer registry data 2023
+27 %
Increase in cancer prevalence in Germany between 2010 and 2020
Development of age-standardized lifetime prevalence according to the OECD country profile. EU: +24 %.
Source: OECD/EC, EU Country Cancer Profile: Germany 2025
Complexity of the evidence

Oncology guidelines are growing substantially

19962019

NCCN guidelines for selected common cancers, average values per guideline.

Page count
26
198
+762 %
Cited references
28
856
+3,057 %
Decision pathways
30
111
+370 %
From our needs assessment
≈ 3 h
Research effort per week for guidelines, studies and approval information
Physicians in hematology and oncology report around three hours of research effort per week.
Needs assessment survey in cooperation with the German Society of Hematology and Medical Oncology (DGHO)
89
FDA oncology approval decisions in 2024, including new products and new indications for already approved products
Source: FDA Oncology Center of Excellence, Annual Report 2024
Sources RKI / ZfKD· OECD / European Commission· JAMA Network Open· FDA OCE· AVOR needs assessment in cooperation with the DGHO

We know this problem from our own clinical and scientific work.

We ourselves work in clinical care, research and data science. Medical decisions rest on ever more evidence, while everyday practice often leaves little time for research. For a single question, guidelines, regulatory information and publications have to be gathered and put into context.

AVOR emerged from exactly this tension. AVOR is not meant to simplify medicine or replace clinical judgement, but to make relevant information faster to find, structured and traceable down to the original source.

News from AVOR

View all posts →
AVOR Medical Intelligence receiving the Health Special Award at the HSBI Startup Award 2026
Award25 September 2026

AVOR wins the Health Special Award at the HSBI Startup Award 2026

AVOR Medical Intelligence received the Health Special Award of the HSBI Startup Award 2026 at the Health Entrepreneurship Day of Bielefeld University of Applied Sciences.

Learn more →
AVOR Medical Intelligence team receiving the Audience Award at the ELSA Pitch Bowl 2026
Award26 June 2026

AVOR wins the Audience Award at the ELSA Pitch Bowl 2026

At the ELSA Pitch Bowl in Göttingen, AVOR received the Audience Award in the public vote.

Learn more →
Award ceremony for the Life Science Special Award at LIFT-OFF 2026
Award28 May 2026

AVOR wins the Life Science Special Award at LIFT-OFF 2026

At the start-up competition of the University of Göttingen, AVOR received the Life Science Special Award.

Learn more →

Contact

If you would like to follow the development of AVOR from an early stage, please get in touch. We particularly welcome enquiries about pilot projects, early access and strategic partnerships.

info@avor.med LinkedIn

Please do not send us any patient data through this form.

We store your details on our own server in Germany in order to answer your enquiry. See our privacy policy.

A medical question?

Ask

Research medical information and check the underlying sources directly yourself.

Try AVOR for free Contact

For medical professionals. Free of charge.

avor.med
AVOR
What would you like to research?
For example: What does the evidence say about treating AML with FLT3-ITD in patients under 60 with no further mutations?
Ask question
Recently researched
AML, FLT3-ITD, under 60›
NSCLC, PD-L1 ≥ 50 %, brain metastases›
Gastric cancer, HER2+, Claudin-18.2+›
Answers may be incomplete or incorrect. Please check against the sources.